Endocrine System Channel
Topics
Medications
Quicklinks
Related Channels

Alogliptin and Pioglitazone

Clinical Effects of Alogliptin and Pioglitazone

Alogliptin and pioglitazone itself has not been studied in clinical trials. However, the combination of these two active ingredients has been studied in people with type 2 diabetes that was not already well controlled with diet and exercise or when using another diabetes medication (metformin [Glucophage®]). In these studies, people given the combination of alogliptin and pioglitazone had a reduction in their hemoglobin A1c (HbA1c) and fasting blood glucose.
 
Effects on Hemoglobin A1c
Hemoglobin A1c (HbA1c) is a test used to measure long-term blood sugar control. People without diabetes and those with well-controlled diabetes usually have HbA1c results that are less than 6 percent. Studies have shown that the higher the HbA1c, the greater the chance for developing long-term problems related to diabetes, such as heart, eye, nerve, and kidney problems.
 
In one study, people taking alogliptin with pioglitazone for 26 weeks lowered their HbA1c by 1.7 percent, on average. In comparison, people taking alogliptin alone lowered their HbA1c by 1 percent, and people taking pioglitazone alone lowered their HbA1c by 1.2 percent. 
 
Effects on Blood Sugar Levels
In the same study, people given the combination of pioglitazone and alogliptin had a lowering of their fasting blood sugar by 50 mg/dL, on average. In comparison, pioglitazone alone lowered fasting blood glucose by 37 mg/dL, on average, and alogliptin alone by 26 mg/dL, on average. 
 

How Does It Work?

As mentioned already, this drug contains two diabetes medicines: alogliptin and pioglitazone. These two medicines work in different ways to control blood sugar.
 
Alogliptin belongs to a group of medicines known as dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down certain hormones known as incretin hormones. These hormones cause insulin to be released from the pancreas (which lowers blood glucose levels) in response to meals. They also reduce the amount of glucagon released by the pancreas, which reduces glucose (sugar) production by the liver.
 
By blocking the DPP-4 enzyme, alogliptin and pioglitazone increases the level of incretin hormones in the blood. This causes more insulin to be made in response to meals and reduces the amount of glucose made by the liver.
 
Pioglitazone belongs to a group of medicines known as thiazolidinediones, or simply "glitazones." Glitazones work by improving insulin sensitivity in muscle and fat tissue. This means it helps the cells in the body respond better to insulin, which lowers blood sugar. It also reduces the amount of glucose released by the liver.
 
Steps to Prevent or Delay Diabetic Nerve Damage

Alogliptin and Pioglitazone Drug Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.